{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:06:10Z","timestamp":1789146370090,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373183"],"award-info":[{"award-number":["82373183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC3404000"],"award-info":[{"award-number":["2023YFC3404000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117268","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:16:15Z","timestamp":1786493775000},"page":"117268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A potent anti-CD47 antibody decoupling anti-tumor efficacy from hematotoxicity"],"prefix":"10.1016","volume":"187","author":[{"given":"Mingxia","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiujiu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongdao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiangjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianwen","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.intimp.2026.117268_bb0005","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1021\/acs.molpharmaceut.4c00950","article-title":"Macrophage membrane-coated nanomedicine enhances Cancer immunotherapy by activating macrophages and T cells","volume":"22","author":"Zhao","year":"2025","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.intimp.2026.117268_bb0010","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1021\/acs.molpharmaceut.4c01277","article-title":"Antitumor research based on drug delivery carriers: reversing the polarization of tumor-associated macrophages","volume":"22","author":"Cao","year":"2025","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.intimp.2026.117268_bb0015","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2026.117268_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189294","article-title":"CD47 as a potent target in cancer immunotherapy: a review","volume":"1880","author":"Ahvati","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.117268_bb0025","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3892\/ol.2024.14389","article-title":"Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (review)","volume":"27","author":"Wu","year":"2024","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.intimp.2026.117268_bb0030","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1007\/s00277-025-06401-2","article-title":"Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia","volume":"104","author":"Sammartano","year":"2025","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117268_bb0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.32604\/or.2023.042383","article-title":"Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy","volume":"32","author":"Chen","year":"2024","journal-title":"Oncol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.117268_bb0040","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann. Hematol."},{"issue":"31","key":"10.1016\/j.intimp.2026.117268_bb0045","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.intimp.2026.117268_bb0050","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2026.117268_bb0055","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.intimp.2026.117268_bb0060","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1073\/pnas.81.21.6851","article-title":"Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains","volume":"81","author":"Morrison","year":"1984","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2026.117268_bb0065","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0022-2836(92)91010-M","article-title":"Antibody framework residues affecting the conformation of the hypervariable loops","volume":"224","author":"Foote","year":"1992","journal-title":"J. Mol. Biol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117268_bb0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/meth.1999.0921","article-title":"Antibody modeling: implications for engineering and design","volume":"20","author":"Morea","year":"2000","journal-title":"Methods"},{"issue":"3","key":"10.1016\/j.intimp.2026.117268_bb0075","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/0022-2836(85)90137-8","article-title":"Domain association in immunoglobulin molecules","volume":"186","author":"Chothia","year":"1985","journal-title":"J. Mol. Biol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117268_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137345","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"issue":"W1","key":"10.1016\/j.intimp.2026.117268_bb0085","doi-asserted-by":"crossref","first-page":"W521","DOI":"10.1093\/nar\/gkae241","article-title":"The EMBL-EBI job dispatcher sequence analysis tools framework in 2024","volume":"52","author":"Madeira","year":"2024","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.intimp.2026.117268_bb0090","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRP\u03b1Fc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"Supplement_1","key":"10.1016\/j.intimp.2026.117268_bb0095","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2019-122793","article-title":"TJC4, a differentiated anti-CD47 antibody with novel epitope and RBC sparing properties","volume":"134","author":"Meng","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2026.117268_bb0100","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1535-7163.MCT-19-1079","article-title":"Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding","volume":"19","author":"Puro","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.intimp.2026.117268_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201832","article-title":"ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. Roberts DD, editor","volume":"13","author":"Kauder","year":"2018","journal-title":"PLoS One"},{"issue":"32","key":"10.1016\/j.intimp.2026.117268_bb0110","doi-asserted-by":"crossref","first-page":"13224","DOI":"10.1073\/pnas.1101398108","article-title":"Functional CD47\/signal regulatory protein alpha (SIRP\u03b1) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo","volume":"108","author":"Legrand","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117268_bb0115","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4049\/jimmunol.1100528","article-title":"Signal regulatory protein \u03b1 regulates the homeostasis of T lymphocytes in the spleen","volume":"187","author":"Sato-Hashimoto","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.117268_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112424","article-title":"IMT030122, a novel engineered EpCAM\/CD3\/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer","volume":"137","author":"Shen","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.117268_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113395","article-title":"Monoclonal antibody targeting CEACAM1 enhanced the response to anti-PD1 immunotherapy in non-small cell lung cancer","volume":"143","author":"Zhao","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117268_bb0130","first-page":"266","article-title":"A pan-allelic human SIRP\u03b1-blocking antibody, ES004-B5, promotes tumor killing by enhancing macrophage phagocytosis and subsequently inducing an effective T-cell response","volume":"7","author":"Niu","year":"2024","journal-title":"Antib. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.117268_bb0135","doi-asserted-by":"crossref","first-page":"432","DOI":"10.21147\/j.issn.1000-9604.2025.03.11","article-title":"Immune cell metabolism in cancer drug resistance: advances in target discovery and clinical translation","volume":"37","author":"Sun","year":"2025","journal-title":"Chin. J. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2026.117268_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109546","article-title":"Disruption of CD47-SIRP\u03b1 signaling restores inflammatory function in tumor-associated myeloid-derived suppressor cells","volume":"27","author":"Zimarino","year":"2024","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.intimp.2026.117268_bb0145","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1038\/s41590-025-02321-5","article-title":"Thrombospondin-1\u2013CD47 signaling contributes to the development of T cell exhaustion in cancer","volume":"26","author":"Weng","year":"2025","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117268_bb0150","first-page":"37","article-title":"Insights into CD47\/SIRP\u03b1 axis-targeting tumor immunotherapy","volume":"1","author":"Zhang","year":"2018","journal-title":"Antib. Ther."},{"key":"10.1016\/j.intimp.2026.117268_bb0155","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jare.2023.10.009","article-title":"Deciphering the role of CD47 in cancer immunotherapy","volume":"63","author":"Liu","year":"2024","journal-title":"J. Adv. Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.117268_bb0160","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.32604\/or.2025.071708","article-title":"CD47-targeted therapy in Cancer immunotherapy: at a crossroads of promise and challenge","volume":"33","author":"Guo","year":"2025","journal-title":"Oncol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117268_bb0165","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41392-024-01765-9","article-title":"Harnessing innate immune pathways for therapeutic advancement in cancer","volume":"9","author":"Hu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2026.117268_bb0170","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/carcin\/bgy041","article-title":"Disrupting CD47-SIRP\u03b1 axis alone or combined with autophagy depletion for the therapy of glioblastoma","volume":"39","author":"Zhang","year":"2018","journal-title":"Carcinogenesis"},{"issue":"17","key":"10.1016\/j.intimp.2026.117268_bb0175","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1073\/pnas.1121623109","article-title":"The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors","volume":"109","author":"Willingham","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"27","key":"10.1016\/j.intimp.2026.117268_bb0180","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody\u2013mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2026.117268_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.943","article-title":"CD47-SIRP\u03b1 blocking-based immunotherapy: current and prospective therapeutic strategies","volume":"12","author":"Bouwstra","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"5473","key":"10.1016\/j.intimp.2026.117268_bb0190","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.intimp.2026.117268_bb0195","first-page":"179","article-title":"Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment","volume":"3","author":"Kaur","year":"2020","journal-title":"Antib. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.117268_bb0200","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12967-023-04710-6","article-title":"Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117268_bb0205","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01385-2","article-title":"SIRP\u03b1-fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47\/SIRP\u03b1 signal pathway via blocking the \u201cdon\u2019t eat me\u201d signal and activating the \u201ceat me\u201d signal","volume":"15","author":"Yu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117268_bb0210","article-title":"CD47\u2013SIRP\u03b1-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immuno-Oncol Technol."},{"issue":"18","key":"10.1016\/j.intimp.2026.117268_bb0215","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.intimp.2026.117268_bb0220","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-25-1826","article-title":"A phase I trial of evorpacept, lenalidomide, and rituximab for patients with B-cell non-Hodgkin lymphoma","volume":"31","author":"Strati","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"4_suppl","key":"10.1016\/j.intimp.2026.117268_bb0225","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2025.43.4_suppl.332","article-title":"Final analysis of the randomized phase 2 part of the ASPEN-06 study: a phase 2\/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric\/gastroesophageal cancer (GC)","volume":"43","author":"Shitara","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117268_bb0230","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11523-025-01130-y","article-title":"A phase 1b\/2 study of the anti-CD47 antibody magrolimab with cetuximab in patients with colorectal Cancer and other solid tumors","volume":"20","author":"Eng","year":"2025","journal-title":"Target. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2026.117268_bb0235","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005517","article-title":"Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity","volume":"10","author":"Qu","year":"2022","journal-title":"J. Immunother. Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:09:07Z","timestamp":1789142947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926011148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":47,"alternative-id":["S1567576926011148"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117268","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A potent anti-CD47 antibody decoupling anti-tumor efficacy from hematotoxicity","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117268"}}